MedTrace Logo

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

NCT00003761 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-02-15

No results posted yet for this study

Summary

This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

Conditions

Interventions

BIOLOGICAL

rV-DF3/MUC1

\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU. \-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination * Level 1 4.76 x 106 PFU * Level 2 4.76 x 107 PFU * Level 3 4.76 x 108 PFU

Sponsors & Collaborators

Principal Investigators

  • Donald W. Kufe, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-03
Primary Completion
2001-04-20
Completion
2001-10-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003761 on ClinicalTrials.gov